Primary progressive multiple sclerosis (PPMS) is a type of multiple sclerosis marked by a steady worsening of neurological function from the onset, without early relapses or remissions. As per Emilio Portaccio et al., 2024, it accounts for around 10-15% of all multiple sclerosis cases. According to the primary progressive multiple sclerosis pipeline analysis by Expert Market Research, there is a growing focus on developing targeted PPMS drugs and therapeutic products. Advances in neuroimmunology and biologics are driving innovation, with promising PPMS therapeutics expected to fuel market growth in the coming years.
Major companies involved in the primary progressive multiple sclerosis pipeline analysis include Sanofi, Kyverna Therapeutics, and others.
Leading drugs and biologics currently in the pipeline include KYV-101, DUOC-01, and Orca-Q, among others.
Advancements in B-cell targeted therapies, expanding clinical trials for remyelination agents, and increased neurodegenerative research funding are accelerating drug development in primary progressive multiple sclerosis.
The Primary Progressive Multiple Sclerosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into primary progressive multiple sclerosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for primary progressive multiple sclerosis. The primary progressive multiple sclerosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The primary progressive multiple sclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with primary progressive multiple sclerosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to primary progressive multiple sclerosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Primary progressive multiple sclerosis (PPMS) is a chronic neurological condition where the immune system attacks the protective covering of nerve fibers, causing gradual and continuous worsening of neurological function without distinct relapses or remissions. It primarily affects the spinal cord and brain, leading to progressive disability from the onset. The exact cause is unknown, but it involves immune-mediated damage.
Primary progressive multiple sclerosis treatment includes disease-modifying therapies like Ocrevus, which slow progression and reduce nerve damage, offering some functional stability and delaying disability over time. In September 2024, the FDA approved Ocrevus Zunovo™ as a subcutaneous treatment for PPMS, offering a twice-yearly, 10-minute injection option with efficacy comparable to its intravenous form.
According to Emilio Portaccio et al., 2024, primary progressive multiple sclerosis (PPMS) accounts for approximately 10-15% of all multiple sclerosis cases, marked by a steady progression of neurological decline. As per Gulfaraz Khan et al., 2025, globally, over 1.89 million people live with multiple sclerosis, with 62,000 new diagnoses in 2021. The prevalence is 23.9 cases per 100,000 population, highest in Sweden, Canada, and Norway. In the United States, northern states report nearly double the incidence compared to southern regions.
This section of the report covers the analysis of primary progressive multiple sclerosis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The primary progressive multiple sclerosis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total primary progressive multiple sclerosis clinical trials with 37%, reflecting a strong focus on early-stage clinical development. Phase II and Phase III each contribute 30%, indicating promising progression toward advanced trials. This balanced pipeline highlights continued innovation, potentially accelerating effective treatment availability.
The drug molecule categories covered under the primary progressive multiple sclerosis pipeline analysis include small molecules, monoclonal antibodies, peptides, cell-based therapies, and gene therapies. The primary progressive multiple sclerosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for primary progressive multiple sclerosis. Immunomodulatory therapies are gaining traction in the treatment pipeline for primary progressive multiple sclerosis. For example, GA Depot, a long-acting form of glatiramer acetate, is under phase 2a clinical investigation. Administered intramuscularly every 28 days, it aims to reduce disease progression and inflammation, offering a potential long-term treatment option for patients with primary progressive multiple sclerosis.
The EMR report for the primary progressive multiple sclerosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed primary progressive multiple sclerosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in primary progressive multiple sclerosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for primary progressive multiple sclerosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of primary progressive multiple sclerosis drug candidates.
KYV-101, sponsored by Kyverna Therapeutics, is a fully human anti-CD19 CAR T-cell therapy being evaluated in the Phase 2 KYSA-7 study. This trial is investigating KYV-101 in adults with refractory primary and secondary progressive multiple sclerosis. The objective is to assess its ability to selectively deplete pathogenic B cells, aiming to reduce neuroinflammation and disease progression.
DUOC-01 is a cell-based therapy derived from CB CD14+ monocytes expanded from donated human umbilical cord blood. Sponsored by the Duke University, this Phase 1a trial is assessing the safety of intrathecal DUOC-01 in adults with primary progressive multiple sclerosis. The study is evaluating its potential to modulate neuroinflammation and repair CNS demyelination.
Orca-Q is an investigational allogeneic T-cell immunotherapy being sponsored by Stanford University for primary progressive multiple sclerosis. This Phase 1 study is evaluating the safety and feasibility of allogeneic hematopoietic cell transplantation using Orca-Q, a donor-derived engineered graft from mobilized peripheral blood, aiming to offer immune system reprogramming without the need for fully matched donors.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Primary Progressive Multiple Sclerosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for primary progressive multiple sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into primary progressive multiple sclerosis collaborations, regulatory environments, and potential growth opportunities.
Upto 25% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share